23G transconjunctival sutureless vitrectomy safe & effective

Article

Twenty-three gauge transconjunctival sutureless vitrectomy is an effective surgical technique for the management of vitreoretinal diseases.

Twenty-three gauge transconjunctival sutureless vitrectomy is an effective surgical technique for the management of vitreoretinal diseases, according to a study published in the February issue of Retina.

Asheesh Tewari and colleagues from the Kresge Eye Institute, Wayne State University School of Medicine, Michigan, US conducted a retrospective chart review of 81 consecutive 23-gauge vitrectomy cases carried out by a single surgeon for various posterior segment conditions.

Mean follow-up was 6.5 months (range: three to nine months). Mean preoperative visual acuity (VA) was 20/150 and final VA was 20/70 (p<0.0001). Mean intraocular pressure (IOP) on the first day postoperatively was 14 mmHg (range: 6 - 28 mmHg). There was a single case of intraoperative retinal tear that required treatment with cryotherapy and 20 eyes of 48 phakic eyes (42%) had worsening cataracts during the postoperative period. There were no recorded cases of endophthalmitis or retinal detachment.

It was the conclusion of the researchers that 23-gauge transconjunctival sutureless vitrectomy is both safe and effective.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.